Neurophth
Dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD656m (Public information from Aug 2023)
Wuhan Hubei (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
* | CNY15.0m | Seed | |
* | CNY130m | Series A | |
CNY400m | Series B | ||
* | $60.0m | Series C | |
* | CNY700m Valuation: CNY3.5b | Series C | |
Total Funding | CAD315m |
Related Content
Recent News about Neurophth
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.